Differing molecular pathology of pancreatic adenocarcinoma in Egyptian and United States patients

International Journal of Cancer

Volumn 119, Issue 6, 2006, Pages 1455-1461

  Soliman, Amr S ^a,e   Bondy, Melissa ^b   Webb, Charity Renee ^b   Schottenfeld, David ^a   Bonner, Joseph ^a   El Ghawalby, Nabih ^b   Soultan, Ahmed ^b   Abdel Wahab, Mohamed ^b   Fathy, Omar ^b   Ebidi, Gamal ^b   Zhang, Qing ^b   Greenson, Joel K ^c   Abbruzzese, James L ^d   Hamilton, Stanley R ^b  

^a UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d MANSOURA UNIVERSITY   (Egypt)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

International differences; K ras; Molecular pathology; p53; Pancreatic cancer

Indexed keywords

GUANINE; THYMINE;

ADULT; AIR POLLUTION; ARTICLE; CODON; EGYPT; EVALUATION; EXON; FEMALE; GADD45 GENE; GENE; GENE MUTATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RIVER; TUMOR SUPPRESSOR GENE; UNITED STATES;

ADENOCARCINOMA; CARCINOMA, PANCREATIC DUCTAL; CASE-CONTROL STUDIES; CELL CYCLE PROTEINS; DNA, NEOPLASM; EGYPT; EXONS; FEMALE; GENES, P53; GENES, RAS; HUMANS; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; UNITED STATES;

EID: 33747487722     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21986     Document Type: Article

References (50)

1. Soliman AS, Bondy ML, Levin B, Hamza MR, Ismail K, Ismail S, Hammam HM, el-Hattab OH, Kamal SM, Soliman AG, Dorgham LA, McPherson RS et al. Colorectal cancer in Egyptian patients under 40 years of age. Int J Cancer 1997;71:26-30.
2. Soliman AS, Bondy ML, Raouf AA, Makram MA, Johnston DA, Levin B. Cancer mortality in Menofeia, Egypt: comparison with U.S. mortality rates. Cancer Causes Control 1999;10:349-54.
3. Soliman AS, Bondy ML, El-Badawy SA, Mokhtar N, Eissa S, Bayoumy S, Seifeldin IA, Houlihan PS, Lukish JR, Watanabe T, Chan AO, Zhu D et al. Contrasting molecular pathology of colorectal carcinoma in Egyptian and Western patients. Br J Cancer 2001;85:1037-46.
4. Soliman AS, El-Ghawalby N, Ezzat F, Bondy ML, Soultan A, Abdel-Wahab M, Fathy O, Ebidi G, Bassiouni N, El-Ghawalbi A, Levin B, Abbruzzese JL. Unusually high rate of young-onset pancreatic cancer in the east Nile delta region of Egypt. Int J Gastrointest Cancer 2002;32:143-51.
5. Siegel FR, Slaboda ML, Stanley DJ. Metal pollution loading, Manzala Lagoon, Nile delta, Egypt: implications for aquaculture. Environ Geol 1994;23:89-98.
6. Stanley DJ, McRea JE, Jr, Waldron JC. Nile delta drill core and sample database for 1985-1994: Mediterranean basin (MEDIBA) program, Report No. 37. Washington, DC: Smithsonian Institution, 1996.
7. Stanley DJ, Warne AG. Nile delta in its destruction phase. J Coast Res 1998;14:794-825.
8. Dekov VM, Komy Z, Araujo F, Van Put A, Van Grieken R. Chemical composition of sediments, suspended matter, river water and ground water of the Nile (Aswan-Sohag traverse). Sci Total Environ 1997; 201:195-210.
9. Reinhardt EG, Stanley DJ, Schwarcz HP. Human-induced desalinization of Manzala lagoon, Nile delta, Egypt: evidence from isotopic analysis of benthic invertebrates. J Coast Res 2001;17:431-42.
10. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
11. Fryzek JP, Garabrant DH, Greenson JK, Schottenfeld D. A review of the epidemiology and pathology of pancreas cancer. Int J Gastrointest Cancer 1997;2:99-100.
12. Blot WJ, Fraumeni JF, Stone BJ. Geographic correlates of pancreas cancer in the United States. Cancer 1978;42:373-80.
13. Ibrahim AS, Hussein H, Ismail K, Hablas A, Bar I, Ramadan M. Cancer profile in Gharbiah-Egypt. Middle East Cancer Consortium, 2002.
14. Yamasawa K, Nio Y, Dong M, Yamaguchi K, Itakura M. Clinicopathological significance of abnormalities in Gadd45 expression and its relationship to p53 in human pancreatic cancer. Clin Cancer Res 2002;8:2563-9.
15. American Joint Committee on Cancer. Exocrine pancreas. In: American joint committee on cancer: AJCC cancer staging manual, 5th edn. Philadelphia, PA: Lippincott, 1997. 121-6.
16. Porta M. Commentary. In: Von Hoff DD, Evans DB, Hruban RH, eds. Pancreatic cancer, 1st edn. Massachusetts: Jones & Bartlett, 2005, 113-17.
17. Begg CB, Zhang ZF. Statistical analysis of molecular epidemiology studies employing case-series. Cancer Epidemiol Biomarkers Prev 1994;3:173-5.
18. Schroeder JC, Weinberg CR. Use of missing-data methods to correct bias and improve precision in case-control studies in which cases are subtyped but subtype information is incomplete. Am J Epidemiol 2001;154:954-62.
19. Hartge P, Chatterjee N, Wacholder S, Brody LC, Tucker MA, Struewing JP. Breast cancer risk in Ashkenazi BRCA1/2 mutation carriers: effects of reproductive history. Epidemiology 2002;13:255-61.
20. Alguacil J, Porta M, Kauppinen T, Malais N, Kogevinas M, Carrato A. PANKRAS II Study Group. Occupational exposure to dyes, metals, polycyclic aromatic hydrocarbons and other agents and K-ras activation in human exocrine pancreatic cancer. Int J Cancer 2003;107:635-41.
21. Chan AO, Soliman AS, Zhang Q, Rashid A, Bedeir A, Houlihan PS, Mokhtar N, Al-Masri N, Ozbek U, Yaghan R, Kandilci A, Omar S et al. Differing DNA methylation patterns and gene mutation frequencies in colorectal carcinomas from Middle Eastern countries. Clin Cancer Res 2005;11:8281-7.
22. Soliman AS, Wang X, DiGiovanni J, Eissa S, Morad M, Vulimiri S. Mahgoub KG, Johnston DA, Do KA, Seifeldin IA, Boffetta P, Bondy ML. Serum organochlorine levels and history of lactation in Egypt. Environ Res 2003;92:110-7.
23. Soliman AS, Vulimiri SV, Kleiner HE, Shen J, Eissa S, Morad M, Taha H, Lukmanji F, Li D, Johnston DA, Lo HH, Lau S et al. High levels of oxidative DNA damage in lymphocyte DNA of premenopausal breast cancer patients from Egypt. Int J Environ Health Res 2004;14:121-34.
24. Kriegel AM, Soliman AS, Zhang Q, El-Ghawalby N, Ezzat F, Soultan A, Abdel-Wahab M, Fathy O, Ebidi G, Bassiouni N, Hamilton SR, Abbruzzese JL et al. Serum cadmium levels in pancreatic cancer patients from the east Nile delta region of Egypt. Environ Health Perspect 2006; 114:113-19.
25. Jen J, Kim H, Piantadosi S, Liu ZF, Levitt RC, Sistonen P, Kinzler KW, Vogelstein B, Hamilton SR. Allelic loss of chromosome 18q and prognosis of colorectal cancer. N Engl J Med 1994;331:213-21.
26. Fujiwara T, Stoiker JM, Watanabe T, Rashid A, Longo P, Eshleman JR, Booker S, Lynch HT, Jass JR, Green JS, Kim H, Jen J et al. Accumulated clonal genetic alterations in familial and sporadic colorectal carcinoma with widespread instability in microsatellite sequence. Am J Pathol 1998; 153:1063-78.
27. Jen J, Powell SM, Papadopoulos N, Smith KJ, Hamilton SR, Vogelstein B, Kinzler KW. Molecular determinants of dysplasia in colorectal lesions. Cancer Res 1994;54:5523-6.
28. Grunewald K, Lyons J, Frohlich A, Feichtinger H, Weger RA, Schwab G, Janssen JW, Bartram CR. High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 1989;43:1037-41.
29. Scarpa A, Capelli P, Villaneuva A, Zamboni G, Lluis F, Accolla R, Mariuzzi G, Capella G. Pancreatic cancer in Europe: Ki-ras gene mutation pattern shows geographical differences. Int J Cancer 1994;57:167-71.
30. Nagata Y, Abe M, Motoshima K, Nakayama E, Shiku H. Frequent glycine-to-aspartic acid mutations at codon 12 of c-Ki-ras gene in human pancreatic cancer in Japanese. Jpn J Cancer Res 1990;81:135-40.
31. Lemoine NR, Jain S, Hughes CM, Staddon SL, Maillet B, Hall PA, Kloppel G. Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastroenterology 1992;102:230-6.
32. Weyrer K, Feichtinger H, Haun M, Weiss G, Ofner D, Weger AR, Umlauft F, Grunewald K. p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas. Lab Invest 1996;74:279-89.
33. Hruban RH, van Mansfeld AD, Offerhaus GJ, van Weering DH, Allison DC, Goodman SN, Kensler TW, Bose KK, Cameron JL, Bos JL. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993;143:545-54.
34. Lohr M, Kloppel G, Maisonneuve P, Lowenfels AB, Luttges J. Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia 2005;7:17-23.
35. Pernick NL, Sarkar FH, Philip PA, Arlauskas P, Shields AF, Vaitkevicius VK, Dugan MC, Adsay NV. Clinicopathologic analysis of pancreatic adenocarcinoma in African Americans and Caucasians. Pancreas 2003; 26:28-32.
36. Yamaguchi K, Chijiiwa K, Torato N, Kinoshita M, Tanaka M. Ki-ras codon 12 point and P53 mutations: a molecular examination of the main tumor, liver, portal vein, peripheral arterial blood and para-aortic lymph node in pancreatic cancer. Am J Gastroenterol 2000;95:1939-45.
37. Song MM, Nio Y, Dong M, Tamura K, Furuse K, Tian YL, He SG, Shen K. Comparison of K-ras point mutations at codon 12 and p21 expression in pancreatic cancer between Japanese and Chinese patients. J Surg Oncol 2000;75:176-85.
38. van der Heijden MS, Kern SE. Molecular genetic alterations in cancer-associated genes. In: Von Hoff DD, Evans DB, Hruban RH, eds. Pancreatic cancer, 1st edn. Massachusetts: Jones & Bartlett, 2005.31-41.
39. Howe JR, Conlon KC. The molecular genetics of pancreatic cancer. Surg Oncol 1997;6:1-18.
40. Porta M, Malats N, Jariod M, Grimalt JO, Rifa J, Carrato A, Guarner L, Salas A, Santiago-Silva M, Corominas JM, Andreu M, Real FX. Serum concentrations of organochlorine compounds and K-ras mutations in exocrine pancreatic cancer. Lancet 1999;354:2125-9.
41. Rall CJ, Yan YX, Graeme-Cook F, Beauchamp R, Yandell DW, Povoski SP, Rustgi AK. Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma. Pancreas 1996;12:10-7.
42. Blanck HM, Tolbert PE, Hoppin JA. Patterns of genetic alterations in pancreatic cancer, a pooled analysis. Environ Mol Mutagen 1999;33:111-22.
43. DiGiuseppe JA, Hruban RH, Goodman SN, Polak M, van den Berg FM, Allison DC, Cameron JL, Offerhaus GJ. Overexpression of p53 protein in adenocarcinoma of the pancreas. Am J Clin Pathol 1994; 101:684-8.
44. Dergham ST, Dugan MC, Arlauskas P, Du W, Vaitkevicius VK, Crissman JD, Sarkar FH. Relationship of family cancer history to the expression of p53, p21WAF-1, HER-2/neu, and K-ras mutation in pancreatic adenocarcinoma. Int J Pancreatol 1997;211:225-34.
45. Ghadirian P, Lynch HT, Krewski D. Epidemiology of pancreatic cancer: an overview. Cancer Detect Prev 2003;27:87-93.
46. Hruban RH, Goggins M, Parsons J. Kern SE. Progression model for pancreatic cancer. Clin Cancer Res 2000;6:2969-72.
47. Weiderpass E, Partanen T, Kaaks R, Vainio H, Porta M, Kauppinen T, Ojajarvi A, Boffetta P, Malats N. Occurrence, trends and environment etiology of pancreatic cancer. Scand J Work Environ Health 1998;24:165-74.
48. Ojajarvi IA, Partanen TJ, Ahlbom A, Boffetta P, Hakulinen T, Jourenkova N, Kauppinen TP, Kogevinas M, Porta M, Vainio HU, Weiderpass E, Wesseling CH. Occupational exposures and pancreatic cancer: a metaanalysis. Occup Environ Med 2000;57:316-24.
49. Porta M, Ayude D, Alguacil J, Jariod M. Exploring environmental causes of altered ras effects: fragmentation plus integration? Mol Carcinog 2003;36:45-52.
50. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363:1049-57.